Lilly, BI's Jardiance still beats Novo’s Rybelsus when it comes to cost-effectiveness: ICER

FiercePharma | November 01, 2019

The Institute for Clinical and Economic Review (ICER) started giving Novo Nordisk a hard time about the cost-effectiveness of its oral version of semaglutide, Rybelsus, before the drug was even approved in September. Now the product has its price tag— $772 per month, on par with comparable injectables—yet ICER still isn’t happy. ICER released a report Friday concluding that if Rybelsus is prescribed as an add-on treatment to metformin in Type 2 diabetes, it will be less cost-effective than Eli Lilly and Boehringer Ingelheim’s Jardiance in the same setting. Rybelsus is the first GLP-1 receptor agonist that’s available in pill form, but Jardiance—a widely prescribed SGLT-2 inhibitor—is also an oral option. Hence “judging from the list price of oral semaglutide, its net price is likely to be much higher than that of competitor oral treatments…that appear to have similar benefits with fewer common side effects,” ICER said in a statement. ICER’s report came on the same day that Novo released its third-quarter earnings, and during a conference call with investors, chief financial officer Karsten Munk Knudsen griped that the cost-effectiveness review didn't take a broad enough approach. "Over decades, this is clearly cost-effective," he said of the new drug.

Spotlight

This former AIDS researcher says a job in translational medicine allows her to make a difference to more lives. A first-hand account of a career at the Novartis Institutes for BioMedical Research. © 2015 Novartis AG.

Spotlight

This former AIDS researcher says a job in translational medicine allows her to make a difference to more lives. A first-hand account of a career at the Novartis Institutes for BioMedical Research. © 2015 Novartis AG.

Related News

PHARMA TECH

Vivera Receives 3rd U.S. Patent Allowance for ZICOH Drug Delivery Device

Vivera Pharmaceuticals, Inc. | May 26, 2022

Vivera is pleased to announce the allowance of its third U.S. patent for ZICOH™, the Company's high-tech, electronic dose-controlled portfolio of drug delivery devices. The patent allowance from the U.S. Patent and Trademark Office secures ZICOH's rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules, and tablets. ZICOH is an electronic dose-controlled delivery device and technology designed to enable real-time communication through the drug supply chain, from drug manufacturers, distributors, and wholesalers to pharmacists, providers, physicians, caregivers, and patients. The device can be programmed to dispense the medication dosage type, amount, and frequency according to the health care provider's orders to ensure compliance with dispensed prescriptions while also implementing controls to help prevent medication misuse and abuse. Later versions of the device will also implement user authentication features, such as fingerprint authorization and facial recognition, to help prevent prescription drugs from being diverted. Medication reminders are another core feature of ZICOH. These reminders can be programmed into the device by the pharmacist per the physician's orders to alert the patient when it's time to take their medication. This feature can be particularly beneficial for patients who forget to take medications on time or for patients and caregivers who manage multiple medications. "ZICOH is a major innovation in the medical device and technology sectors. This device is going to make it easier than ever for patients to comply with their medication regimens, regardless of how complex they are." Mehdi Hatamian, Ph.D., Chief Scientific Advisor for Vivera This third patent differs from the device's two previously issued patents in that it specifically pertains to the dispensing of tablets, capsules, and pills. The device has already secured its patent rights as a secure, smart liquid and inhaler delivery device with automated dose delivery, measurement, and management. "We are proud of the progress we have made on the development of ZICOH's multiplatform uses and technology," said Paul Edalat, CEO and Chairman of Vivera. "The way that Tesla revolutionized the automotive industry, and the way Apple created a category for smart devices, is what Vivera is doing to the prescription dispensing industry. ZICOH will forever change the way that medications are prescribed and dispensed, and Vivera is reaching the milestones to get there in a fraction of the time projected." Vivera is looking forward to bringing ZICOH to market. The Company has already initiated the device's design and is looking forward to having a working prototype by late summer 2022. About Vivera Pharmaceuticals Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT® sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH™, a smart dose-controlled medical device. It also has patents pending on its telemedicine station, MDZone. With multiple divisions, including its pharmaceutical, neurosciences, medical technology, biosciences, and advanced diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.

Read More

PHARMA TECH

Prescryptive Health Launches Comprehensive Pharmacy Management Platform to Expand the Scope of Community Pharmacists

Prescryptive Health | October 06, 2021

Healthcare technology company Prescryptive Health today announced that MyRx PRO is now operational nationwide. The pharmacy management platform allows pharmacists to digitize their business with new revenue opportunities through profitable clinical services and a deeper patient engagement experience. Today we change the course of the community pharmacist, by empowering them to expand their business and meet new customers through new services, all on our secure platform. Pharmacists are central to community health, and we are proud to offer a system to help them transform for the digital age. - Chris Blackley, CEO of Prescryptive Health At the core of MyRx PRO are turn-key clinical services, which build in patient engagement, inventory management, reporting, and billing all on one platform. This includes critical COVID-19 care—testing, vaccinations, and monoclonal antibody treatment—and flu services for the ongoing public health crisis. MyRx PRO pharmacists already on the platform had a lift in annual revenue up to 25%; by offering relevant services, pharmacists can grow their business while providing the healthcare needed in their local communities. New patients find these services through Prescryptive's patient-friendly mobile solution, MyRx.io. I'm getting new patients at my counter every day thanks to Prescryptive, MyRx PRO allows me to offer more services efficiently so I can focus on what matters most: patient care. - Vincent Chiffy, owner of Parkway Drugs in Utica, NY. MyRx PRO also features SmartPRICE™ with AI-driven intelligent pricing capabilities and a solution for cash-paying customers. Unlike popular cash discount cards, SmartPRICE™ saves patients up to 80% on prescriptions without exorbitant fees charged to local pharmacies by third parties. MyRx PRO is available nationwide today, with new clinical services added continually. About Prescryptive Health Prescryptive Health is a healthcare technology company delivering solutions that empower consumers. Prescryptive's secure, mobile-first products connect consumers, pharmacists, and employers, ultimately providing people with the information they need to make informed decisions and take control of their health.

Read More

PHARMACY MARKET

Sensyne Health and Phesi Form a Joint Commercial Development Partnership with a Leading Pharmaceutical Company

Sensyne Health, Phesi | May 24, 2021

Sensyne Health plc, the Clinical AI company, today announced that it has entered a joint commercial clinical development partnership in an undisclosed disease area with a major pharmaceutical company that is an existing client of Phesi with its U.S.-based strategic partner Phesi Inc. Sensyne and Phesi have entered into a joint commercial collaboration with a pharmaceutical customer for the first time since forming a strategic alliance in January 2021. The development work will consist of comparing anonymized and de-identified real-world patient data available to Sensyne with Phesi's clinical trial data to optimize the design of a clinical trial program for the client. This collaboration's financial terms have not been disclosed. About Sensyne – Phesi Strategic Alliance Sensyne and Phesi decided to partner on an exclusive basis to offer synthetic clinical trial arms and clinical decision support tools that combine clinical trial data with real-world patient data under the terms of the strategic partnership arrangement. Many of the world's leading pharmaceutical and biotechnology companies are among Phesi's clients. About Sensyne Health Sensyne Health plc is a clinical artificial intelligence company with a unique business model – a for-profit plc with a positive social impact that shares its financial returns with health systems. Clinical AI is used by the company in the healthcare and life science industries. Sensyne provides remote patient monitoring and real-time decision-making services of healthcare for medical institutions and their patients. Sensyne analyses large complex anonymized data sets in life sciences to assist life sciences companies in accelerating the development of new medicines. About Phesi Inc. Phesi is a profitable, privately held company headquartered in Connecticut, United States. The goal of the organization is to enable data-driven drug development and commercialization through predictive analytics powered by patient-centric data science. Phesi's integrated offerings include the entire clinical development process, from development planning and indication evaluation to protocol evaluation and design (including a synthetic control arm), site selection, and trial implementation management. The company works with life science companies to deliver novel therapies quicker and at a lower cost, including all stages of clinical development and a wide range of indications, including rare diseases.

Read More